Please ensure Javascript is enabled for purposes of website accessibility

Here's Why TG Therapeutics Jumped 35.5% in December

By Maxx Chatsko - Jan 6, 2020 at 12:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two triple-combination therapies delivered impressive results in early-stage studies, which propelled the stock to a 170% gain in 2019.

What happened

Shares of TG Therapeutics (TGTX 2.38%) gained over 35% last month, according to data provided by S&P Global Market Intelligence. The pharma stock ended the year on a high note thanks to two impressive data presentations at the Annual Meeting of the American Society of Hematology (ASH).

The company is developing two separate triple-combination therapies as treatments for relapsed (meaning a cancer has returned after treatment) or refractory (meaning a cancer was resistant to treatment) non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Both triple combinations achieved very high response rates in small, early-stage studies. 

That was enough to propel shares to a 170% gain in 2019.

A businessman tossing cash into the air.

Image source: Getty Images.

So what

Combination therapies are becoming increasingly common in drug development. If multiple active pharmaceutical ingredients prove safe together, then combination treatments can benefit from multiple or synergistic modes of action. TG Therapeutics is all-in.

Both of the company's triple-combination therapies in blood cancers contain a proprietary duo of ublituximab (an experimental monoclonal antibody) and umbralisib (an experimental small-molecule inhibitor of PI3K delta and CK1 epsilon, two proteins involved in cellular growth). The combination is known as U2. 

In the triple-combination therapy of U2 and the approved cancer drug venetoclax, all 13 CLL patients in the study responded to treatment. All nine evaluated in time for the ASH data cutoff had undetectable levels of minimal residual disease in their blood, while seven met that benchmark in their bone marrow.

In the triple-combination therapy of U2 and a proprietary asset called TG-1701, six of seven people with NHL or CLL responded to treatment at the lowest dose of TG-1701 tested. 

Now what

TG Therapeutics could be onto something with its triple-combination drug candidates in blood cancers. Of course, the results presented at ASH are from small, early-stage studies. Investors will need to see these impressive results supported by larger clinical trials in the next few years and know that those successfully treated to date maintain their responses for the long haul. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TG Therapeutics Stock Quote
TG Therapeutics
$5.17 (2.38%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.